HRTX

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2001, for AP Pharma, Inc. (formerly Advanced Polymer Systems, Inc.). The company operates primarily through strategic alliances, earning revenue from royalties, license fees, and the sale of analytical standards. In July 2000, the company sold its cosmeceutical and toiletry business lines to R.P. Scherer Corporation, which are now reported as discontinued operations. The company is currently focused on developing its Biochronomer system for implantable and injectable pharmaceutical applications.

Key Financial Metrics

Debt and Liquidity: The company has no outstanding debt as of March 31, 2001, having repaid all obligations in July 2000 using proceeds from the sale of its cosmeceutical business. Total liquid assets (cash, cash equivalents, and marketable securities) totaled approximately $21.05 million.

Material Changes vs. Prior Period

• Revenue Growth: Total revenues increased 33% to $970,735 from $730,248. Royalties and license fees rose 59% to $675,262, driven by the launch of Carac(TM) for actinic keratoses. Product revenues from analytical standards declined slightly by 3% to $295,473.
• Profitability: The company reported a net loss of $1.12 million compared to a net income of $220,297 in the prior year. This shift was primarily due to a $158,355 loss from discontinued operations (legal fees) and a significant increase in operating expenses.
• Operating Expenses: Total operating expenses increased 66% to $2.19 million. Research & Development (R&D) expenses surged 149% to $1.38 million due to pre-clinical trials for the Biochronomer system. General & Administrative expenses increased 8% to $688,390.
• Interest Income: Interest income increased significantly to $348,169 from $65,093, attributed to interest earned on the $25 million proceeds from the July 2000 asset sale.
• Cash Flow: Net cash used in operating activities increased to $1.46 million from $63,000, reflecting higher R&D spending.

Outlook, Risks, and Management Commentary

Outlook: Management expects existing cash, marketable securities, and revenue streams to be sufficient to meet working capital requirements for the foreseeable future. Capital is being directed toward pre-clinical trials for the Biochronomer system.

Risks and Contingencies:

• Legal Proceedings: The company is defending a lawsuit filed by Douglas and Albert Kligman alleging a partnership regarding product development. The plaintiffs seek damages in excess of $75,000. The company denies liability and expects no material adverse effect on financial statements.
• Discontinued Operations: The loss from discontinued operations in Q1 2001 was primarily driven by legal fees associated with the Kligman lawsuit.
• Forward-Looking Statements: Results are subject to risks regarding product development, regulatory approval, and market acceptance.

Investor Verification Checklist

• Verify the status and potential financial impact of the Kligman lawsuit, specifically regarding the $75,000+ claimed damages and associated legal fees.
• Confirm the progress and timeline of pre-clinical trials for the Biochronomer system, which drove the 149% increase in R&D expenses.
• Review the terms of the Carac(TM) partnership with Dermik Laboratories/Aventis to understand the sustainability of the 59% increase in royalty revenue.
• Assess the liquidity runway given the $1.46 million quarterly cash burn rate from operations.
• Check for any updates on the potential $26.5 million in milestone payments from the R.P. Scherer Corporation sale of the cosmeceutical business.